Mona Tomaschko

Mona Tomaschko

Auto-generated profile, based on publicly available information

Mona Tomaschko

The Francis Crick Institute 1 London

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2024 in Cancer Research
Verified
Journal Article
Open access
PDF file
JBJesse Boumelha
Jesse Boumelha
ACAndrea de Castro
Andrea de Castro
NBNourdine Bah
Nourdine Bah
HCHongui Cha
Hongui Cha
STSophie de Carné Trécesson
Sophie de Carné Trécesson
JDJulian Downward
Julian Downward
Oncogenic KRAS impairs antitumor immune responses. As effective strategies to combine KRAS inhibitors and immunotherapies have so far proven elusive, a better understanding of the mechanisms by which oncogenic KRAS drives immune evasion is needed to identify approaches that could sensitize KRAS-mutant lung cancer to immunotherapy. In vivo CRISPR–Cas9 screening in an immunogenic murine lung cancer model identified mechanisms by which oncogenic KRAS promotes immune evasion, most notably via upregulation of immunosuppressive COX2 in cancer cells. Oncogenic KRAS potently induced COX2 in both mouse and human lung cancer, which was suppressed using KRAS inhibitors. COX2 acted via prostaglandin E2 (PGE2) to promote resistance to immune checkpoint blockade (ICB) in lung adenocarcinoma. Targeting COX2/PGE2 remodeled the tumor microenvironment by inducing proinflammatory polarization of myeloid cells and influx of activated cytotoxic CD8+ T cells, which increased the efficacy of ICB. Restoration of COX2 expression contributed to tumor relapse after prolonged KRAS inhibition. These results provide the rationale for testing COX2/PGE2 pathway inhibitors in combination with KRASG12C inhibition or ICB in patients with KRAS-mutant lung cancer. Significance: COX2 signaling via prostaglandin E2 is a major mediator of immune evasion driven by oncogenic KRAS that promotes immunotherapy and KRAS-targeted therapy resistance, suggesting effective combination treatments for KRAS-mutant lung cancer.

13 November 2025 in Science
Verified
Journal Article
Open access
JKJoseph E. Klebba
Joseph E. Klebba
NRNilotpal Roy
Nilotpal Roy
SBSteffen M. Bernard
Steffen M. Bernard
SGStephanie Grabow
Stephanie Grabow
MHMelissa A. Hoffman
Melissa A. Hoffman
MPMatthew P. Patricelli
Matthew P. Patricelli
Genetic disruption of the RAS binding domain (RBD) of phosphoinositide 3-kinase alpha (PI3Kα) impairs the growth of tumors driven by the small guanosine triphosphatase RAS in mice and does not affect PI3Kα’s role in insulin-mediated control of glucose homeostasis. Selectively blocking the RAS-PI3Kα interaction may represent a strategy for treating RAS-dependent cancers as it avoids the toxicity associated with inhibitors of PI3Kα lipid kinase activity. We developed compounds that bind covalently to cysteine 242 in the RBD of PI3K p110α and block RAS activation of PI3Kα activity. In mice, inhibitors slow the growth of RAS mutant tumors and human epidermal growth factor receptor 2–overexpressing tumors, particularly when combined with other inhibitors of the RAS/mitogen-activated protein kinase pathway, without causing hyperglycemia.

15 July 2024
Verified
Other
Open access
PDF file
JBJesse Boumelha
Jesse Boumelha
ACAndrea de Castro
Andrea de Castro
NBNourdine Bah
Nourdine Bah
HCHongui Cha
Hongui Cha
STSophie de Carné Trécesson
Sophie de Carné Trécesson
JDJulian Downward
Julian Downward
Supplementary Figure 9. Oncogenic KRAS drives tumor-intrinsic expression of COX-2 in LUAD

15 July 2024
Verified
Other
Open access
PDF file
JBJesse Boumelha
Jesse Boumelha
ACAndrea de Castro
Andrea de Castro
NBNourdine Bah
Nourdine Bah
HCHongui Cha
Hongui Cha
STSophie de Carné Trécesson
Sophie de Carné Trécesson
JDJulian Downward
Julian Downward
Supplementary Figure 6. Tumor-intrinsic COX-2 remodels the lung tumor microenvironment

17 June 2026
Verified
Other
Open access
PDF file
JBJesse Boumelha
Jesse Boumelha
ACAndrea de Castro
Andrea de Castro
NBNourdine Bah
Nourdine Bah
HCHongui Cha
Hongui Cha
STSophie de Carné Trécesson
Sophie de Carné Trécesson
JDJulian Downward
Julian Downward
Supplementary Figure 4. COX-2 deficient tumors are sensitized to anti-tumor immunity

17 June 2026
Verified
Other
Open access
PDF file
JBJesse Boumelha
Jesse Boumelha
ACAndrea de Castro
Andrea de Castro
NBNourdine Bah
Nourdine Bah
HCHongui Cha
Hongui Cha
STSophie de Carné Trécesson
Sophie de Carné Trécesson
JDJulian Downward
Julian Downward
Supplementary Figure 2. KRAS-driven inhibition of tumor-intrinsic IFN signaling promotes immune evasion